BioDrugs. 2026 Mar 30. doi: 10.1007/s40259-026-00774-0. Online ahead of print.
ABSTRACT
OBJECTIVE: This study examines the monoclonal antibody innovation landscape through patent activity and market data.
METHODS: A dedicated dataset was constructed by linking multiple sources (Antibody Society, Orange Book, Ark Patent Intelligence, US Patent and Trademark Office, PATSTAT, Purple Book, US Veterans Affairs, US-FDA, and ORBIS), covering patents registered between 1986 and 2019. Data analysis comprised six components: (i) a general description of the dataset, (ii) an examination of monoclonal antibody patents and approval trends, (iii) an analysis of therapeutic indications, (iv) a characterization of patent holders and producers through descriptive and network analyses, (v) an assessment of shareholder influence, including common-ownership patterns, and (vi) an evaluation of monoclonal antibody prices.
RESULTS: The dataset included 63 monoclonal antibodies, 1732 unique patents, 89 active pharmaceutical ingredients, 34 producers, and 214 therapeutic indications, of which 36.5% were single indication, while the average number of secondary indications was 3.78. Roche, Johnson & Johnson, Eli Lilly, Amgen, and Novartis led reference medicine production, while Amgen and Pfizer were notable in biosimilars, with only five companies producing both. Shareholders such as BlackRock, UBS, Vanguard, and JPMorgan exerted strong market influence in monoclonal antibody production. Prices were extremely high, averaging US$127,430 per course or year (s = US$142,509), with 42.1% of monoclonal antibodies priced above US$100,000.
CONCLUSIONS: While monoclonal antibodies have transformed modern medicine and improved safety and effectiveness, their persistently high prices, reinforced by market concentration and financial investor influence, raise serious concerns for equity and social welfare.
PMID:41910914 | DOI:10.1007/s40259-026-00774-0
